GlassScriptPhysician profile
Golda O Johnson
NPI 1780668236
$652.75
in general payments reported to CMS, 2019-2025
14 companies · $28.31 in 2025
The $28.31 reported for 2025 was less than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $18.73 · 2021: $59.29 · 2022: $60.56 · 2023: $26.25 · 2024: $153 · 2025: $28.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $207.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $170.37 | 2020-2025 | Cabenuva, Dovato |
| Janssen Pharmaceuticals, INC | $92.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.52 | 2022 | |
| Dynavax Technologies Corporation | $42.84 | 2021 | |
| Sanofi-Aventis U.S. LLC | $41.75 | 2019 | |
| Novo Nordisk INC | $38.83 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $36.06 | 2019-2021 | |
| Pfizer INC. | $29.69 | 2024 | |
| Lilly USA, LLC | $28.56 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.25 | 2023 | |
| Ironwood Pharmaceuticals, INC | $19.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.61 | 2019 | |
| Abbvie INC. | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Golda Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.